vs

Side-by-side financial comparison of EnerSys (ENS) and Revvity (RVTY). Click either name above to swap in a different company.

EnerSys is the larger business by last-quarter revenue ($919.1M vs $772.1M, roughly 1.2× Revvity). Revvity runs the higher net margin — 12.7% vs 9.8%, a 2.9% gap on every dollar of revenue. On growth, Revvity posted the faster year-over-year revenue change (5.9% vs 1.4%). EnerSys produced more free cash flow last quarter ($171.3M vs $161.8M). Over the past eight quarters, Revvity's revenue compounded faster (9.0% CAGR vs 0.5%).

EnerSys is a stored energy systems and technology provider for industrial applications. The company manufactures reserve-power and motive-power batteries, battery chargers, power equipment, battery accessories and outdoor equipment enclosures.

Revvity, Inc. is an American company in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines.

ENS vs RVTY — Head-to-Head

Bigger by revenue
ENS
ENS
1.2× larger
ENS
$919.1M
$772.1M
RVTY
Growing faster (revenue YoY)
RVTY
RVTY
+4.4% gap
RVTY
5.9%
1.4%
ENS
Higher net margin
RVTY
RVTY
2.9% more per $
RVTY
12.7%
9.8%
ENS
More free cash flow
ENS
ENS
$9.5M more FCF
ENS
$171.3M
$161.8M
RVTY
Faster 2-yr revenue CAGR
RVTY
RVTY
Annualised
RVTY
9.0%
0.5%
ENS

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
ENS
ENS
RVTY
RVTY
Revenue
$919.1M
$772.1M
Net Profit
$90.4M
$98.4M
Gross Margin
30.1%
Operating Margin
13.5%
14.5%
Net Margin
9.8%
12.7%
Revenue YoY
1.4%
5.9%
Net Profit YoY
-21.3%
3.9%
EPS (diluted)
$2.40
$0.86

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ENS
ENS
RVTY
RVTY
Q4 25
$919.1M
$772.1M
Q3 25
$951.3M
$698.9M
Q2 25
$893.0M
$720.3M
Q1 25
$974.8M
$664.8M
Q4 24
$906.2M
$729.4M
Q3 24
$883.7M
$684.0M
Q2 24
$852.9M
$691.7M
Q1 24
$910.7M
$649.9M
Net Profit
ENS
ENS
RVTY
RVTY
Q4 25
$90.4M
$98.4M
Q3 25
$68.4M
$46.7M
Q2 25
$57.5M
$53.9M
Q1 25
$96.5M
$42.2M
Q4 24
$114.8M
$94.6M
Q3 24
$82.3M
$94.4M
Q2 24
$70.1M
$55.4M
Q1 24
$60.9M
$26.0M
Gross Margin
ENS
ENS
RVTY
RVTY
Q4 25
30.1%
Q3 25
29.1%
53.6%
Q2 25
28.4%
54.5%
Q1 25
31.2%
56.5%
Q4 24
32.9%
Q3 24
28.5%
56.3%
Q2 24
27.9%
55.7%
Q1 24
27.9%
54.6%
Operating Margin
ENS
ENS
RVTY
RVTY
Q4 25
13.5%
14.5%
Q3 25
9.7%
11.7%
Q2 25
9.7%
12.6%
Q1 25
13.5%
10.9%
Q4 24
15.7%
16.3%
Q3 24
11.2%
14.3%
Q2 24
10.7%
12.4%
Q1 24
8.9%
6.8%
Net Margin
ENS
ENS
RVTY
RVTY
Q4 25
9.8%
12.7%
Q3 25
7.2%
6.7%
Q2 25
6.4%
7.5%
Q1 25
9.9%
6.4%
Q4 24
12.7%
13.0%
Q3 24
9.3%
13.8%
Q2 24
8.2%
8.0%
Q1 24
6.7%
4.0%
EPS (diluted)
ENS
ENS
RVTY
RVTY
Q4 25
$2.40
$0.86
Q3 25
$1.80
$0.40
Q2 25
$1.46
$0.46
Q1 25
$2.39
$0.35
Q4 24
$2.88
$0.77
Q3 24
$2.01
$0.77
Q2 24
$1.71
$0.45
Q1 24
$1.48
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ENS
ENS
RVTY
RVTY
Cash + ST InvestmentsLiquidity on hand
$450.1M
$919.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
$7.3B
Total Assets
$4.0B
$12.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ENS
ENS
RVTY
RVTY
Q4 25
$450.1M
$919.9M
Q3 25
$388.6M
$931.4M
Q2 25
$346.7M
$991.8M
Q1 25
$343.1M
$1.1B
Q4 24
$463.2M
$1.2B
Q3 24
$407.9M
$1.2B
Q2 24
$344.1M
$2.0B
Q1 24
$333.3M
$1.7B
Total Debt
ENS
ENS
RVTY
RVTY
Q4 25
Q3 25
Q2 25
Q1 25
$1.1B
Q4 24
Q3 24
Q2 24
Q1 24
$802.0M
Stockholders' Equity
ENS
ENS
RVTY
RVTY
Q4 25
$1.9B
$7.3B
Q3 25
$1.9B
$7.4B
Q2 25
$1.9B
$7.6B
Q1 25
$1.9B
$7.6B
Q4 24
$1.8B
$7.7B
Q3 24
$1.8B
$7.9B
Q2 24
$1.8B
$7.9B
Q1 24
$1.8B
$7.8B
Total Assets
ENS
ENS
RVTY
RVTY
Q4 25
$4.0B
$12.2B
Q3 25
$4.1B
$12.1B
Q2 25
$4.1B
$12.4B
Q1 25
$4.0B
$12.4B
Q4 24
$4.0B
$12.4B
Q3 24
$4.0B
$12.8B
Q2 24
$3.6B
$13.4B
Q1 24
$3.5B
$13.4B
Debt / Equity
ENS
ENS
RVTY
RVTY
Q4 25
Q3 25
Q2 25
Q1 25
0.57×
Q4 24
Q3 24
Q2 24
Q1 24
0.46×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ENS
ENS
RVTY
RVTY
Operating Cash FlowLast quarter
$184.6M
$182.0M
Free Cash FlowOCF − Capex
$171.3M
$161.8M
FCF MarginFCF / Revenue
18.6%
21.0%
Capex IntensityCapex / Revenue
1.4%
2.6%
Cash ConversionOCF / Net Profit
2.04×
1.85×
TTM Free Cash FlowTrailing 4 quarters
$441.3M
$509.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ENS
ENS
RVTY
RVTY
Q4 25
$184.6M
$182.0M
Q3 25
$218.0M
$138.5M
Q2 25
$968.0K
$134.3M
Q1 25
$135.2M
$128.2M
Q4 24
$81.1M
$174.2M
Q3 24
$33.6M
$147.9M
Q2 24
$10.4M
$158.6M
Q1 24
$147.6M
Free Cash Flow
ENS
ENS
RVTY
RVTY
Q4 25
$171.3M
$161.8M
Q3 25
$197.1M
$120.0M
Q2 25
$-32.1M
$115.5M
Q1 25
$104.9M
$112.2M
Q4 24
$56.8M
$149.8M
Q3 24
$3.3M
$125.6M
Q2 24
$-25.7M
$136.6M
Q1 24
$129.7M
FCF Margin
ENS
ENS
RVTY
RVTY
Q4 25
18.6%
21.0%
Q3 25
20.7%
17.2%
Q2 25
-3.6%
16.0%
Q1 25
10.8%
16.9%
Q4 24
6.3%
20.5%
Q3 24
0.4%
18.4%
Q2 24
-3.0%
19.7%
Q1 24
20.0%
Capex Intensity
ENS
ENS
RVTY
RVTY
Q4 25
1.4%
2.6%
Q3 25
2.2%
2.6%
Q2 25
3.7%
2.6%
Q1 25
3.1%
2.4%
Q4 24
2.7%
3.4%
Q3 24
3.4%
3.3%
Q2 24
4.2%
3.2%
Q1 24
2.7%
Cash Conversion
ENS
ENS
RVTY
RVTY
Q4 25
2.04×
1.85×
Q3 25
3.19×
2.97×
Q2 25
0.02×
2.49×
Q1 25
1.40×
3.03×
Q4 24
0.71×
1.84×
Q3 24
0.41×
1.57×
Q2 24
0.15×
2.87×
Q1 24
5.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ENS
ENS

Energy Systems$399.5M43%
Motive Power$352.0M38%
Services$92.6M10%
Transferred Over Time$38.2M4%
Other$36.8M4%

RVTY
RVTY

Immunodiagnostics$240.8M31%
Life Sciences$191.4M25%
Reproductive Health$149.3M19%
Segment Operating Income$132.0M17%
Software$62.3M8%

Related Comparisons